J&J speeds into new bladder cancer trial
The company takes another project from Taris into phase 3 as it chases a $5bn market.
ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
